Dermata Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gerald T. Proehl
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3525 Del Mar Heights Road San Diego CA United States of America 92130
- IPO Date
- Aug 13, 2021
- CIK
- 0001853816
- Website
- dermatarx.com
- Similar Companies
- Business
- Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company focused on developing and commercializing topical pharmaceutical products for medical skin diseases and aesthetic conditions using its proprietary Spongilla lacustris-derived platform technology. Founded in 2014 and headquartered in San Diego, California, the company targets the U.S. dermatology market with product candidates that address inflammatory and noninflammatory lesions through mechanical exfoliation, anti-microbial action, and chemical keratolysis delivered via once-weekly applications. Its lead product candidate, XYNGARI (formerly DMT310), advances in Phase 3 clinical trials for moderate-to-severe acne vulgaris and has completed Phase 1b proof-of-concept for mild-to-moderate psoriasis and moderate-to-severe papulopustular rosacea; DMT410 facilitates topical intradermal delivery of macromolecules such as botulinum toxin type A, with Phase 1b proof-of-concept completed for axillary hyperhidrosis and aesthetic indications including fine lines and wrinkles; DMT400 supports dermal penetration of biologics for psoriasis, acne, and other conditions. In September 2025, Dermata announces a strategic pivot from prescription dermatology development to over-the-counter (OTC) pharmaceutical products incorporating Spongilla technology, with preparations underway for a mid-2026 launch of its inaugural once-weekly acne treatment kit followed by expansions into psoriasis and seborrheic dermatitis offerings. The company maintains a clinical trial collaboration with Revance Therapeutics, Inc. to evaluate XYNGARI with DAXXIFY for hyperhidrosis, while pursuing partnerships for DMT410 commercialization and registering a $100 million shelf for flexible financing amid its cash runway into Q2 2026.
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Dermata Therapeutics (DRMA) Projected to Post Earnings on Monday
Dermata Opens a New Chapter with the Release of Tome Skincare
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis